
Diagonal Bio Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Diagonal Bio
Access all reports
Diagonal Bio AB operates as a biotechnology company in Sweden. The company is focused on the development of drug candidate for treatment of diabetes and obesity, based on its technology for targeting the GLP-1 receptor. The company also develops small molecules for pharmaceutical and diagnostic purposes. It offers DiabNext, which is in Phase II trial for dibenzo-p-dioxin (DCDX)-induced significant reduction in pulmonary hypertension syndrome (PH). The company is based in Lund, Sweden.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
DIABIO
Country
🇸🇪 Sweden